Boston, MA 03/06/2014 (wallstreetpr) – Biocryst Pharmaceuticals, Inc. (NASDAQ:BCRX) now deserves increased attention from investors if that was not there already. The company just published a medical research report that all but suggests that it could crack Marburg virus. And that could mean massive gains for the company and its investors if the drug it is developing finds its way into human treatment system.
The company participates in the biotech field concerned with the development, design and optimization of drugs aimed at tackling pathogenic diseases. Shares of Biocryst Pharmaceuticals, Inc. (NASDAQ:BCRX) were up 0.63 percent to $12.83 in the last session.
Study Successful so far
Biocryst Pharmaceuticals, Inc. (NASDAQ:BCRX) reported in the published study that it believes its drugs BCX4430 that is developed in partnership with other organizations, has high chances of success.The drug has so far been tested in protected lab animals and the results are encouraging. It was found that the drug had the required ability to interfere with the replication of Marburg virus when injected into monkeys, mice and even if inhaled by guinea pigs.
The progress in with BCX4430 is dealing with the ravaging Marburg virus is that all the six animals in which it was tried after 48 hours of infection were able to survive. Biocryst Pharmaceuticals, Inc. (NASDAQ:BCRX) is involving the U.S. Army Medical Research team in the development of BCRX. And principal researcher at the army institute, Travis Warren confirmed the findings.
The promise
Biocryst Pharmaceuticals, Inc. (NASDAQ:BCRX) and the army believe that if BCX4430 proves equally successful in humans, it will be an important milestone towards protection against biological weapons. It will be such an important protection for the U.S. army as well as people in virus prone areas.
Marburg virus for which BCX4430 is being developed against has human fatality rate of 90 percent. So then, Biocryst Pharmaceuticals, Inc. (NASDAQ:BCRX) hopes that it could begin Phase I clinical trial of BCX4430 on humans as early as 2015. The company has already received $22 million towards pursuing FDA approval.
